Bristol Myers Squibb Company

BMY

Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.

Revenue
+6.93%
EPS
−2.78%
Free cash flow
−36.0%
Total debt
−12.5%

Quarter to September 2026, against a year earlier

59.49 1.15 +1.97%
Market cap
$119.3B
P/E
12.9×
Fwd P/E FY26e
12.0×
Dividend yield
4.32%
F-score
8/9
ROIC
13.2%
Net debt / EBITDA
2.6×
Payout ratio
0.6×

Q3 2026 quarterly report Bristol Myers Squibb cut its full-year earnings guidance, one of four health-care companies to do so as government funding and drug pricing changed. Read it in the report

Latest quarter Q3 FY2026 · quarter to September 2026

Revenue growth has picked up three quarters running, from 1.30% to 6.90%.

Q3 FY2026 and the seven quarters before it
Quarter Revenue, $m Growth, % Op. margin, % EPS, $
Q3 FY26 13,069 6.9 19.4 1.05
Q2 FY26 12,973 5.7 31.5 1.62
Q1 FY26 11,489 2.6 28.2 1.31
Q4 FY25 12,502 1.3 11.8 0.53
Q3 FY25 12,222 2.8 25.5 1.08
Q2 FY25 12,269 0.6 14.4 0.64
Q1 FY25 11,201 (5.6) 26.5 1.20
Q4 FY24 12,342 7.5 1.4 0.04

Against the consensus: revenue beat by 4.07% ($13.1B v $12.6B); adjusted EPS beat by $0.14 ($1.35 v $1.21).

Growth is on the same quarter a year earlier, and EPS is diluted. Negative figures in brackets.

Reports Feb 4, 2027 · Q4 FY26 · consensus EPS $1.53

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 119,250
Revenue ttm 50,033
Net income ttm 9,241
Free cash flow ttm 9,286
Net debt Q 30,296
Valuation
P/E 12.9
Forward P/E FY26e 12.0
Price / sales 2.4
Forward P/S FY26e Powerpack
Price / FCF 12.8
Price / book 5.1
Financial health
Current ratio Q 1.6 (at or above 1.5: strong)
Debt / equity Q 1.8
Interest coverage Q —
Growth
Revenue growth FY26e +4.2%
EPS growth FY26e +4.9%
EPS growth FY27e +3.8%
EPS growth, 5 yrs e −4.9% (below 0%: weak)
Insiders
Net sold 12m 3
Sells 12m 4
Buys 12m 0
Owned by insiders 0.2%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales 11.27% 2.54% 1.45%
Cash Flow 21.00% 0.15% 2.71%
Earnings 16.25% 0.00% 3.69%
Book Value 2.52% (13.35%) (15.91%)

Valuation

The price implies free cash flow after share-based pay growing 3.6% a year for ten years. It grew 28.5% a year over the last ten.

Implied
3.6%
10 years, reported
28.5%
Open the model
P/E against its own 10 years 5.32%
10-year low 10-year high
P/S against its own 10 years 17.72%
10-year low 10-year high
P/B against its own 10 years 43.99%
10-year low 10-year high
EV/Sales against its own 10 years 11.91%
10-year low 10-year high
EV/FCF against its own 10 years 67.63%
10-year low 10-year high

Dividends raised 5 years running

Yield
4.32%
Annual rate
2.52
Payout ratio
55.9%
Growth, 2018–26
+5.84%/yr
  1. 1.60 ’18
  2. 1.64 ’19 +2
  3. 2.29 ’20 +40
  4. 1.47 ’21 −36
  5. 2.16 ’22 +47
  6. 2.28 ’23 +6
  7. 2.40 ’24 +5
  8. 2.48 ’25 +3
  9. 2.52 ’26 +2
paid change on the year, % Powerpack

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

2.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 19,427 20,776 22,561 26,145 42,518 46,385 46,159 45,006 48,300 48,194 50,033 +10.6% 50,234 48,801 40,543 (5.6%)
Gross margin, % 74.42 71.05 71.34 69.10 72.31 78.57 78.04 76.24 71.08 71.08 69.24 (3.3) pt
EBT 5,915 5,131 5,968 4,975 (6,871) 8,098 7,713 8,440 (8,379) 9,328 11,332 +5.2%
EBT margin, % 30.45 24.70 26.45 19.03 (16.16) 17.46 16.71 18.75 (17.35) 19.36 22.65 (11.1) pt
Net income 4,507 975 4,947 3,460 (8,995) 7,014 6,345 8,040 (8,933) 7,055 9,241 +5.1%
Per share, $
Per share, $ Revenue 11.63 12.63 13.82 15.33 18.83 20.88 21.67 21.75 23.83 23.69 24.49 +8.2%
Earnings 2.67 0.61 3.03 2.02 (3.99) 3.15 2.97 3.88 (4.41) 3.47 4.52 +3.0%
Cash flow 1.83 3.21 4.33 4.82 6.22 7.30 6.13 6.70 7.49 6.96 5.21 +16.0%
Capex (0.73) (0.64) (0.58) (0.49) (0.33) (0.44) (0.52) (0.58) (0.62) (0.64) (0.67) (1.3%)
Free cash flow 1.10 2.57 3.74 4.32 5.89 6.86 5.61 6.11 6.88 6.32 4.55 +21.4%
Book value 9.78 7.20 8.65 30.32 16.78 16.21 14.61 14.25 8.08 9.10 11.46 (0.8%)
Shares, m 1,671 1,645 1,633 1,705 2,258 2,221 2,130 2,069 2,027 2,034 2,039 +2.2%
Valuation, ×
Valuation, × P/E 22.27 100.51 17.16 29.05 0.00 19.79 24.25 13.60 0.00 15.59 12.91 24.2
P/S 5.11 4.85 3.76 4.19 3.29 2.99 3.33 2.43 2.37 2.28 2.38 3.5
P/B 6.08 8.51 6.01 2.12 3.70 3.85 4.95 3.70 7.00 5.93 5.09 5.2
EV/Sales 5.13 4.91 3.70 5.38 4.11 3.58 3.99 3.04 3.18 2.99 2.99 4.0
EV/FCF 54.10 24.17 13.65 19.09 13.15 10.90 15.40 10.80 11.01 11.22 16.10 18.3
Cash, $m
Cash, $m Operating cash flow 3,058 5,275 7,066 8,210 14,052 16,207 13,066 13,860 15,190 14,156 10,652 +18.6%
Capex (1,215) (1,055) (951) (836) (753) (973) (1,118) (1,209) (1,248) (1,311) (1,366) +0.8%
Free cash flow 1,843 4,220 6,115 7,374 13,299 15,234 11,948 12,651 13,942 12,845 9,286 +24.1%
Balance, $m
Balance, $m Working capital 4,863 5,291 7,062 11,050 11,112 11,394 5,383 9,508 6,006 5,973 11,014 +2.3%
Net debt 358 1,150 (1,410) 31,340 34,845 27,587 30,067 27,492 38,790 34,438 30,296 +66.1%
Shareholders’ equity 16,347 11,847 14,127 51,698 37,882 36,006 31,118 29,485 16,388 18,506 23,404 +1.4%
Returns, %
Returns, % ROA 13.62 2.99 14.36 4.17 (7.26) 6.14 6.14 8.36 (9.53) 7.72 9.96 (5.9) pt
ROIC 22.13 24.67 29.33 3.74 (5.90) 7.96 7.88 9.26 (9.49) 11.01 13.19 (11.1) pt
ROE 28.97 7.14 37.88 10.45 (20.13) 18.93 18.85 26.48 (39.01) 40.43 44.01 +11.5 pt
People
People Employees 25,000 23,700 23,300 30,000 30,250 32,200 34,300 34,100 34,100 32,500 — +3.0%
Revenue/emp, $m 0.78 0.88 0.97 0.87 1.41 1.44 1.35 1.32 1.42 1.48 — +7.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026

Business profile

Updated

Bristol Myers Squibb is a biopharmaceutical company that discovers, develops, licenses, manufactures and sells prescription medicines for serious diseases. Its work spans cancer, blood disorders, immune diseases, cardiovascular conditions and neuroscience. It sells medicines worldwide, mainly through wholesalers, distributors and specialty pharmacies, while promoting their approved uses to healthcare professionals.

Its products include Opdivo, a cancer medicine used in several tumor types, and Eliquis, an oral medicine used to reduce stroke risk in certain patients and to treat blood clots. Camzyos treats adults with symptomatic obstructive hypertrophic cardiomyopathy, a heart condition; Cobenfy treats schizophrenia in adults. Breyanzi is a cell therapy for certain blood cancers.

Where the money comes from and where it goes Fiscal 2025

Fiscal 2025: revenue by regions, and margins
United States 33,279 69.05%
International 13,828 28.69%
Other 1,087 2.26%
Gross margin 71.08%
Operating margin 19.36%
Pre-tax margin 19.36%

Revenue by segment since 2009

Bristol Myers Squibb Company vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NVS Novartis AG $277.7B 28.8× 24.0× FY26e +4.67% (above 0%: growing) −68.81% (below 0%: shrinking) −17.81% (below 0%: shrinking) 75.99% 12.26% Compare
AZN AstraZeneca PLC $272.1B 24.6× 24.2× FY26e +6.70% (above 0%: growing) +23.46% (above 0%: growing) +1.99% (above 0%: growing) 81.82% 27.07% Compare
AMGN Amgen Inc. $237.4B 25.2× 24.0× FY26e +8.45% (above 0%: growing) +19.39% (above 0%: growing) −13.98% (below 0%: shrinking) 73.10% 35.79% Compare
GILD Gilead Sciences, Inc. $207.8B — (loss-making) — (loss-making) +6.83% (above 0%: growing) −20.16% (below 0%: shrinking) +21.13% (above 0%: growing) 81.07% 41.71% Compare
PFE Pfizer Inc. $158.2B 38.8× 18.7× FY26e −0.43% (below 0%: shrinking) −9.68% (below 0%: shrinking) +20.02% (above 0%: growing) 75.71% 22.14% Compare
NVO Novo Nordisk A/S $128.6B 9.8× — +3.87% (above 0%: growing) −17.14% (below 0%: shrinking) −14.75% (below 0%: shrinking) 76.97% 29.06% Compare
BMY Bristol Myers Squibb Company $119.3B 12.9× 12.0× FY26e +6.93% (above 0%: growing) −2.78% (below 0%: shrinking) −35.95% (below 0%: shrinking) 68.28% 19.40%
SNY Sanofi $111.3B 22.8× — +13.89% (above 0%: growing) +8.21% (above 0%: growing) +99.60% (above 0%: growing) 76.16% 28.53% Compare
GSK GSK PLC Sponsored ADR $95.9B 16.4× 15.5× FY26e +3.75% (above 0%: growing) −23.88% (below 0%: shrinking) +62.44% (above 0%: growing) 73.11% 23.93% Compare
Median of peers $183.0B 24.6× 24.0× +5.69% −13.41% +11.01% 76.08% 27.80%

All 21 Drug Manufacturers General stocks →

From the latest earnings call

Updated

  • Chief Financial Officer David Elkins said growth in Eliquis more than offset generic-driven declines elsewhere in the legacy portfolio, while the growth portfolio expanded.
  • Elkins expects Eliquis revenue to step down in 2027 and said Bristol Myers Squibb is on track to achieve productivity efficiencies by year-end.

Analyst rating changes each firm’s latest, last six months

Firm Date Action Rating Target Change
Wells Fargo Nov 2, 2026 Target cut Hold 65.00 → 60.00 −7.69%

Largest institutional holders 13F, quarter to Jun 30, 2026

Held by institutions 81.67%
Held by the ten largest 39.91%
Holder Shares Stake Change
Vanguard 202.27m 9.90% +2.11m
BlackRock 180.38m 8.83% +8.70m
State Street 102.41m 5.01% +3.84m
JPMorgan Chase 71.71m 3.51% −20.76m
Charles Schwab 67.60m 3.31% +6.48m
Geode Capital Management 56.44m 2.76% +1.16m
Norges Bank 36.87m 1.80% +36.87m
Bank of America 34.05m 1.67% +1.46m
T. Rowe Price 31.73m 1.55% +21.46m
UBS 31.72m 1.55% +1.80m
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Pay and ownership Proxy statement filed Mar 25, 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 21.88m 16.86m 105.00
2024 18.79m 21.20m 105.00
2022 20.05m 35.06m 123.00
2021 19.78m 16.51m 103.00
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Bristol Myers Squibb Company (BMY) Latest News

What happened

  1. Results Bristol Myers Squibb raised its 2026 revenue outlook as its growth portfolio sales rose 12% to about $7.7 billion.
  2. Other Bristol Myers Squibb reported preliminary open-label Phase 3 findings showing symptom improvements with KarXT in Alzheimer’s-related psychosis.
  3. Leadership Bristol Myers Squibb combined its research and development teams under Cristian Massacesi, effective January 1, 2027.
  4. Other Bristol Myers Squibb reported sustained efficacy and no new safety signals in 56-week Phase 3 data for pediatric Camzyos patients.
16 more headlines
All BMY news, as stories →

BMY metrics, ten years each

stockrow.com/BMY · Data as of Nov 18, 2026 · For information only; not investment advice. · © 2026 stockrow.com